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Abstract Normal colonic epithelial cells undergo maturation as they traverse the crypt to the lumenal surface. The 
binding of lectins to goblet cell mucins and other glycoconjugates changes as the cells migrate and differentiate. Additional 
stepwise modifications in glycoconjugate expression occur in premalignant and malignant neoplasms that may be detected 
by lectin binding studies. The lectins Dolichos biflorusagglutinin (DBA) and soybean agglutinin (SBA) have been developed 
as markers of differentiation in normal-appearing colonic epithelium. Using a quantitative biometric system to score tissues, 
reduced levels of lectin binding have been found in rectal tissue from patients with familial adenomatous polyposis (FAP) 
and hereditary nonpolyposis colorectal cancer. The lectin Amaranthus caudatus agglutinin (ACA) binds to a cytoplasmic 
glycoconjugate expressed at the base of the colonic crypt and serves as a possible proliferation marker in the distal, but not 
proximal, colon. ACA binding increases in tandem with increased levels of proliferation (using BrdU incorporation) in 
neoplastic tissues. Binding by the peanut lectin (PNA) occurs late in the adenoma-to-carcinoma sequence - in larger 
adenomas and in cancers - and serves as a marker of advancing neoplasia. Lectins identify the stepwise changes that 
occur during normal differentiation, proliferation and in advancing neoplasia. By selectingthe appropriate probe, biomarkers 
may be developed for early, intermediate, and late events in colorectal cancer. o 1992 WiIpy-Liss, inc. 
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Intermediate biomarkers of neoplastic pro- 
gression are an important goal in the study of 
colorectal cancer. Optimal biomarkers would 
be easy to obtain, would provide a means to  
measure increased risk for the development of 
cancer, and would be modified in a positive 
direction upon the introduction of appropriate 
changes in lifestyle or  introduction of effective 
chemopreventive agents. Most of the pre- 
viously developed intermediate biomarkers 
require the procurement of fresh tissue with 
stringent requirements on handling and 
processing, which can limit the acquisition of 
data. This communication will review the use 
of lectins as histochemical probes of glycopro- 
tein biomarkers that are expressed in colo- 
rectal tissues. Lectins have been identified 
that are useful as markers of proliferation, 
differentiation, and malignant transform- 
ation in the human colon. Other investigators 
have emphasized that proliferation, differ- 
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entiation, and transformation are related but 
separate processes, and in all likelihood no 
single probe is capable of providing insight 
into all three aspects of cellular behavior. 
Panels of lectins may be selected that can be 
used to analyze these three behaviors in the 
colon, and importantly, these probes may be 
used on fixed, paraffin-embedded tissue 
sections, regardless of the duration of their 
storage. 
PRO LI F E RATION, D IFF E R ENTl AT1 0 N , 
AND MALIGNANT TRANSFORMATION IN 
THE COLON 
Proliferation 
Cellular proliferation occurs in the lower 
portion of the normal colonic crypt. After cell 
division, one cell becomes a daughter cell 
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which then migrates towards the luminal 
surface [ 11. Proliferation has traditionally 
been estimated by the incorporation of DNA 
precursors, such as 3H-thymidine followed by 
autoradiography o r  the incorporation of 
bromodeoxyuridine (BrdU) followed by immu- 
nohistochemistry [21. Other groups have 
measured the presence of proliferation- 
associated proteins using the monoclonal 
antibody Ki-67 o r  antibodies t o  the 
proliferating cell nuclear antigen (PCNA). 
Additional approaches have involved 
measurement of the activity of ornithine 
decarboxylase (ODC) which is required for the 
generation of polyamines and proliferation [31. 
Differentiation 
Differentiation has  been indirectly 
measured using 3H-thymidine o r  BrdU 
incorporation. This permits an estimation of 
the total labeling index as well as inappro- 
priate expansion or shift of the proliferating 
pool into the upper portions of the crypt [2]. 
However, both of these approaches require 
that fresh tissue be incubated with DNA 
precursors immediately after it is obtained. 
This obviates the possibility of examining 
material obtained previously, and requires 
that the tissue be obtained in conjunction with 
a tissue culture facility. Moreover, these 
methods do not measure differentiation 
directly; rather, they measure the failure to 
repress DNA synthesis. 
Newly produced epithelial cells differentiate 
as they migrate from the base of the colonic 
crypt to  the surface. Although hyperproli- 
feration often occurs in the setting of impaired 
cellular differentiation, these two processes 
are not always linked t o  one another. 
Relatively few markers of epithelial cell differ- 
entiation have ever been developed for the 
human colon [4]. 
Malignant Transformation 
Hyperproliferation is a characteristic of 
neoplastic lesions, and it has been observed 
that this phenomenon occurs in certain pre- 
malignant lesions as well [3]. Although the 
changes that occur in the normal-appearing 
colonic epithelium from people at high risk for 
colon cancer are complex, there is evidence to 
suggest that hyperproliferation precedes the 
development of neoplasia, at least in some 
instances E1-3,51. 
The appearance of neoplasia in  the 
colorectum is associated with a wide range of 
phenotypic changes. Prominent among these 
is the increased expression of a variety of 
tumor-associated glycoproteins. Tumor mark- 
ers are first found in benign neoplastic colonic 
lesions, ie., adenomatous polyps, and increase 
in expression as  the lesions grow and 
degenerate into cancers 161. These would 
appear t o  be suitable intermediate bio- 
markers; however, as a group, they tend t o  
occur relatively late in  the neoplastic 
sequence. 
GLYCOCONJUGATE MARKERS OF 
BIOLOGICAL ACTIVITY IN THE COLON 
Lectins are naturally-occurring aggluti- 
nins, most of which are derived from plant 
seeds, that may be used to identify o r  purify 
specific glycoconjugate structures. Lectins 
have been used for over ten years as 
histochemical probes in the colon, and some 
have been developed to  help identify each of the 
above mentioned biological activities. 
Lectins As Proliferation Markers 
The lectin Amaranthus caudatus agglut- 
inin (ACA) is a recently characterized lectin 
that labels cytoplasmic glycoconjugates at the 
base of the normal human colonic crypt. ACA 
recognizes the T-antigen (GalP1,3 GalNAca-0- 
ser/thr) o r  its sialylated forms (NeuAca2,S 
Galj31,3GalNAc or  NeuAca2,3 Ga11,3 
(NeuAca2,6) GalNAc) [71. Lectin histo- 
chemistry was performed using formalin- 
fixed, paraffin-embedded tissue sections that 
were hydrated, incubated with a biotinylated 
lectin, and developed with peroxidase con- 
jugated streptavidin 181. Labeling is greatly 
increased in  adenomatous polyps and 
cancers, where there is no compartment- 
alization of labeling as seen in the normal 
colon 181. 
A study was undertaken to compare ACA 
labeling (using biotinylated lectin and avidin- 
biotin-peroxidase t o  localize lectin binding) 
with BrdU incorporation in freshly obtained 
colonic tissues from patients with negative 
family histories for colorectal cancer who had 
just undergone a colonoscopy that revealed no 
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neoplastic lesions [9]. After 4 hrs of incu- 
bation with BrdU, approximately 10% of cells 
were labeled in each colonic crypt, the labeling 
was compartmentalized in the lower two 
thirds of the crypt, and there was no difference 
in labeling index between biopsies taken from 
proximal o r  distal colons. In adenomatous 
polyps over 20% of cells were labeled, and 
approximately 40% of cells were labeled in 
adenocarcinomas using the same technique. 
Using ACA histochemistry, labeling was seen 
in the lower two thirds of the crypt in 96.1 k 
2.4% of colonic crypts and in 2.4 1.3% of the 
upper third of crypts in the distal human 
colon. However, in the proximal colon, 
labeling was seen in the lower two thirds of 
87.9 5 4.6% of crypts and in the upper one third 
in 21.2 3.7%. Thus, ACA was a reliable 
marker of the proliferative region only in the 
distal colon. ACA labeled 76% of glands in 
adenomatous polyps and 93% of glands in 
cancers. Those lesions that showed increased 
proliferation and loss of compartmentaliza- 
tion using BrdU showed similar changes 
using ACA. BrdU (and 3H-thymidine) label 
individual cells that are synthesizing DNA. 
ACA is somewhat different, and labels con- 
tiguous groups of cells in the proliferative 
region. The precise molecular species labeled 
by ACA at the base of the colonic crypt is still 
unidentified. 
ACA was used to  examine rectal biopsies 
of normal-appearing tissues of patients with 
Familial Adenomatous Polyposis (FAP) and 
hereditary nonpolyposis colon cancer 
(HNPCC). Since many of these tissues were 
obtained by colonoscopic biopsy and were not 
oriented such that the entire crypt could be 
evaluated in each instance, a biometric 
scoring system was devised whereby each 
crypt was scored from 0-4+ depending upon 
the intensity of labeling. By counting 100 
crypts, a score was developed for each biopsy 
that ranged from 0 ( i e . ,  no labeling in any 
crypt) to  400 ( i e . ,  4+ labeling in all 100 crypts). 
The average score in a group of normal rectal 
biopsies was 65 f 33. The labeling score in 
HNPCC was similar (74 2 70), but included 
five outliers that had an average labeling 
score of 203 43, which was similar to  the 
average scores in FAP (224 2 76). Thus, excess 
labeling with ACA was seen in FAP, 
compatible with its known hyperproliferative 
characteristics, and a small subset of patients 
with HNPCC appeared t o  have the same 
abnormality [S]. Although many questions 
remain to  be addressed with ACA, it is a 
candidate marker for the proliferative pool of 
cells in the distal normal human colon and in 
neoplastic lesions. 
Lectins As Differentiation Markers 
As noted above, markers of cellular 
differentiation in the human colon have been 
less well explored than proliferation markers. 
However, a series of lectins has been devel- 
oped that serve this function [4]. The lectins 
Dolichos biflorus agglutinin (DBA) and soy- 
bean agglutinin (SBA) label goblet cell mucin 
in the normal colon with progressively 
increasing intensity moving from the base t o  
the surface of the crypt. Contrariwise, the 
lectins Ricinus communis agglutinin1 
(RCA1) and Bauhinia purpurea agglutinin 
(BPA) label goblet cell mucin most intensely in 
the lower portion of the crypt and the intensity 
decreases progressively as the cells migrate 
towards the lumen. DBA and SBA label 
terminal a-N-acetylgalactosamine (GalNAc) 
structures whereas RCAl and BPA label 
terminal P-galactose (P-Gal) residues. Based 
upon the careful structural work of Podolsky 
on oligosaccharides purified from human 
colonic mucin [10,11], a reasonable inter- 
pretation is that immature sugar side chains 
are produced in the lower portion of the crypt, 
and as the cells differentiate and migrate to  
the surface, a terminal a-GalNAc residue is 
added to the immature chain. However, this 
speculation has not yet been confirmed. 
Using global assessment, a reduction in 
DBA labeling has been found in mucins in 
colon cancers, adenomatous polyps, and rec- 
tal biopsies from patients with chronic 
ulcerative colitis. Using the more rigorous 
biometric described above (resulting in scores 
from 0-400) a significant reduction in DBA 
labeling was found in microscopic polyps of 
patients with FAP. Of interest, significant 
reductions were also seen in rectal biopsies 
obtained from patients at risk for HNPCC [121. 
With this background, it would be interesting 
to  determine whether lectin markers of 
differentiation can be used as intermediate 
biomarkers to assign neoplastic risk t o  colonic 
tissues o r  to  assess the impact of chemo- 
preventive programs in patients who are at 
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TABLE 11. Neoplastic Progression in Ulcerative Colitis 
Colitis --- Dysplasia --- Carcinoma 
Normal -> Hyperproliferative --> Dysplasia Carcinoma 
Phenot-ype NL' Repair --> Indeterminate ?--> LGD ?--> HGD ---> Cancer 
Putative 
Genetic Lesions 
aneuploidy [20] ?+ ?+ 







DBA NL (+++) ++ ++ ++ ++ +I- 141 
PNA Golgi Golgi Golgi te U 
(mucin) (rnucin) 
'%same as seen in normal colonic tissues (see Table 1); LGD=low grade dysplasia; HGD=high grade dysplasia; 2Golgi=faint 
labeling seen but limited to the supranuclear region and presumed to represent the Golgi apparatus; lectin abbreviations - see text 
Lectins As Tumor Markers 
Lectin markers of malignant transfor- 
mation have also been developed. Peanut 
agglutinin (PNA) binds t o  the T-antigen, 
which is expressed in the mucin secreted by 
most colorectal cancers [4]. Of interest, this 
lectin binds to  adenomatous polyps in a step- 
wise fashion that correlates with other indi- 
cators of malignant risk in the polyp such as 
size, villous content, and the degree of dys- 
plasia [6]. PNA has been found to  be a marker 
of early neoplastic change in the colons of 
CF-1 mice treated with carcinogen [131, and in 
a marmoset model of spontaneous colitis and 
colon cancer [141. Of interest, PNA is a 
differentiation marker in the proximal colon 
of CF-1 mice, where it selectively binds goblet 
cell mucin in the lower half of the colonic 
crypt [13]. By contrast, PNA does not bind 
anywhere in the normal human colonic crypt. 
PNA is not a specific marker for colon cancer, 
since faint degrees of labeling can be seen in 
inflamed colons [ 151, and moreover, labeling is 
found in hyperplastic polyps of the colon, 
which do not behave as neoplasms [6]. PNA 
binds t o  glycoconjugates of first trimester 
human fetal colon, making it an oncofetal 
marker [161. 
GENETIC CONTROL OF MARKER 
EXPRESSION 
The sequential changes in glycoconjugate 
expression in the adenoma-to-carcinoma 
sequence are outlined in Table 1, and cor- 
related with putative sequential changes that 
occur a t  the genetic level during the genesis of 
a neoplasm 117-221. It is tempting to  speculate 
a possible cause and effect relationship 
between the genetic changes and the altered 
expression of mucin structure. 
A similar, highly speculative correlation 
can be drawn between the abnormal 
expression of mucin-type glycoproteins in 
ulcerative colitis in the putative dysplasia-to- 
cancer sequence in that disease (Table 2). Of 
interest, the appearance of glycoconjugates 
that are bound by PNA appear relatively late 
in both schemes, at approximately the time 
that the ras gene mutation is thought to  
appear [17,19,21,22]. The genetic events 
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responsible for the selective expression of 
glycoproteins in colonic tissues of different 
biological behavior remains to be explored. 
SUMMARY AND CONCLUSIONS 
Lectins have been found that serve as 
markers of proliferation, differentiation, and 
malignant transformation. Lectin binding 
studies can be performed on fixed, paraffin- 
embedded tissues, including archival tissues 
that have been stored for prolonged periods. 
Lectins may be conjugated with fluorescein 
for fluorescence microscopy o r  with biotin for 
peroxidase labeling that utilizes light micro- 
scopy. Tissue biometrics have been developed 
t o  score the labeling, which permits a 
quantitative assessment of partial changes in 
tissue expression of glycoconjugates. Early 
events in the colorectal neoplasia progression 
sequence include increases in proliferation 
and a partial failure of complete cellular 
differentiation. These may be assayed using 
the lectins ACA, DBA, and SBA. Later events 
involve the total loss of expression of 
differentiation markers and the appearance of 
the tumor antigen recognized by PNA. The 
clinical utility of these markers in identifying 
patients a t  high risk for colon cancer or  for 
measuring the impact of chemopreventative 
agents on the colon remains t o  be tested. 
Depending on the needs of the study, a panel of 
lectins may be selected, histochemical scores 
may be quantitated by observers blinded to  the 
therapy, and these studies may be repeated 
serially over time. The limitation of this 
approach is that an invasive procedure will be 
required to obtain tissue for labeling. The use 
of colonic emuent or  fecal material for these 
studies might be unsatisfactory because of the 
abundant presence in the colonic lumen of 
enzymes that degrade glycoprotein structures. 
In spite of these shortcomings, lectins appear 
to  be among the most promising probes to  be 
developed as intermediate biomarkers of 
neoplasia in the colon. 
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